
Skyrizi: An injected biologic for moderate to severe plaque psoriasis. It blocks interleukin-23, a signal that sits high up in the psoriasis chain, and after two starting doses it is given about four times a year. Vtama: A once-daily steroid-free cream for plaque psoriasis. It can be used anywhere on the body, including the face and skin folds, and some people stay clear for months after stopping.


Choose for moderate to severe psoriasis when you want high clearance with only about four injections a year.
Choose for psoriasis or eczema anywhere on the body when you want a once-daily non-steroid with no time limit.
Can you take them together?
Vtama can be used on remaining plaques while on Skyrizi. It does not interact with the biologic.
Compare uses by strength of evidence. Evidence level describes confidence in a benefit, not its size.










Blocks IL-23: Binds this immune messenger before it reaches its receptor. Turns down inflammatory T cells: Reduces signals that keep the psoriasis cycle active. Helps plaques clear: Excess skin buildup and inflammation gradually decrease.
Risankizumab selectively targets the p19 subunit of IL-23, not IL-12. The T-cell and skin changes are a simplified downstream interpretation.

Activates AhR: Binds a receptor that helps regulate skin-cell behavior. May rebalance inflammation: Changes in immune signaling may help calm skin. May support the skin barrier: Changes in barrier proteins may help skin function.
Tapinarof is an AhR agonist; the specific therapeutic mechanisms are unknown. Anti-inflammatory and barrier effects are proposed from experimental evidence and are explicitly qualified.
Two starting doses close together, then a long steady interval. Not adjusted for body weight.
Starting dose: 150 mg as one injection.
Second dose: 150 mg, four weeks after the first.
Usual dose: 150 mg every 12 weeks — about four injections a year after the first year.
If it stops working: There is no approved higher dose or shorter interval for psoriasis. Losing response means reviewing the diagnosis, not injecting more often.
How long: Long term, with no set end point, while it works and is tolerated.
When to Apply: Once a day, at whatever time you will remember. A thin layer over the plaques, rubbed in. It can go on the face, eyelids, armpits, groin and under the breasts, which sets it apart from a steroid. Wash your hands afterwards unless your hands are being treated.
How to Start: Once daily from day one, on every plaque you want treated. No ramp-up, and no cap on how much of the body can be covered, so it does not have to be rationed the way a strong steroid does.
If It Irritates: Small red bumps around hair follicles are the most common problem and usually appear in the first few weeks. Most are not infection and often settle without stopping. Stinging or a rash where you applied it is the other pattern, and that one is worth showing your doctor, because a true contact allergy means stopping.
If It’s Not Working: There is one strength, so there is nothing to increase. Give it a full twelve weeks. If plaques are still thick then, the conversation is about adding something else, phototherapy, or moving to a tablet or injection.
Any time of day. The calendar matters more here than with a weekly drug. Twelve weeks is long enough that people lose track, so put every dose date in your phone and book the next reminder the day you inject.
Take it out of the fridge 15 to 30 minutes before and let it warm on the counter. Cold liquid stings. No hot water, no microwave.
Inject into the front of the thigh or the belly, at least two inches from the navel. The back of the upper arm works if someone else is doing it. Rotate the site, avoid skin that is bruised, tender, hard or scarred, and never inject through a plaque. Ask for training before the first dose. Used devices go in a sharps container.
Inject as soon as you remember, then count twelve weeks from that day. If it has been much longer than twelve weeks, call the prescriber first so the schedule can be reset.
Everyone is screened for tuberculosis before the first dose — a skin test or TB blood test, plus a chest X-ray if that is positive. Dormant TB is treated first. This class probably carries less TB risk than the TNF blockers, but screening is not optional.
Hepatitis B and C are usually checked at the same time.
After that there is no fixed blood test schedule. Risankizumab does not need the regular liver and blood count testing methotrexate does. Monitoring is clinical: the skin, whether infections are more frequent, whether the dose dates are kept. TB testing is repeated yearly or by exposure risk.
There is no boxed warning. The most common side effects reported are upper respiratory infections, headache, tiredness, fungal skin infections and injection site reactions. Serious allergic reactions are rare but are why the first dose is often given with someone trained nearby.
No blood tests are required. There is nothing to check on a lab report, which is one of the practical arguments for a topical over a tablet.
Monitoring is a look at the skin and a conversation, usually at about twelve weeks. Two things get asked about: folliculitis, and whether it is a few bumps or enough to be a problem; and whether the treated skin has become itchy and inflamed in a new way, which points to contact dermatitis rather than psoriasis.
Long term there is no organ risk to track and no skin thinning to watch for, so there is no maximum duration. What is genuinely not known yet is what many years of continuous use looks like, because the drug is recent. A common pattern is to treat until clear, stop, and restart when plaques come back.
Approximate windows, not promises.
First few minutesThe injection: A sharp sting for a few seconds, then redness or a small welt. Settles within a day or two.
First few minutesApplying it: A thin layer once a day on the plaques.
Weeks 1 to 4Starting: Itch settles first. Scale lifts and plaques thin.
Weeks 1 to 4Starting: Scale and roughness ease before the redness does, often by week four. Folliculitis shows up now if it is going to, usually small tender bumps in hair-bearing areas.
Weeks 4 to 16Working: Most of the change happens here, from the second dose on. Plaques flatten and redness fades from the middle out, often leaving a paler or darker mark.
Week 16Judge it here: Most people reached 90 percent clearer skin, and many were clear or nearly clear. Joints improve on the same timeline.
3 to 6 monthsScalp, palms and soles: Slower than the trunk and limbs.
6 to 12 monthsNails: Last to change, because a nail takes months to grow out.
Between dosesSteady state: Most people notice no dip. If plaques reliably return in the last few weeks, say so.
Weeks 4 to 8Working: Plaques flatten and shrink, and color fades from red toward pink or brown.
Weeks 8 to 12Judge it here: Trials measured their main result at twelve weeks, and many people were still improving then. A meaningful minority reached clear or almost clear skin — a realistic target, not a promise.
After stoppingRemission: Unlike a steroid, it does not usually rebound. People who cleared completely often stayed clear for months before restarting.
Sorted by what to do about them.
The list price runs to tens of thousands of dollars a year. Almost nobody pays that; what you pay depends on your plan.
It is brand only — no generic, no biosimilar — so there is no cheaper equivalent to switch to. That is a real difference from adalimumab.
Prior authorization is close to universal. Most plans require documented failure of something cheaper first — phototherapy, methotrexate, sometimes another biologic. Denials are usually about missing records rather than the drug, and appeals succeed reasonably often when the history is documented.
Manufacturer copay cards can cut the cost to very little with commercial insurance. By law they cannot be used with Medicare or Medicaid. For those plans, or no insurance, the manufacturer's patient assistance program and independent foundations are the usual routes. Terms change often.
One practical note: because doses are twelve weeks apart, a change of insurance or a formulary switch in January can land in the middle of a dosing gap. Check coverage before the next dose is due, not the week it is.
Brand only, with no generic. It is one of the more expensive topicals for psoriasis and costs far more than a generic steroid or generic calcipotriene.
Coverage varies and prior authorization is common; plans frequently want to see a topical steroid, and often a vitamin D analog, tried first. Manufacturer copay cards exist and the terms change, so check the current one.
Because a tube covers only so much, cost climbs quickly with widespread psoriasis, which is one of the main reasons people end up on a tablet or injection instead.
A large protein grown in living cells rather than a chemical made in a factory. That is why it is injected, and why it lives in the fridge.
After the first two doses, four weeks apart, yes. The drug stays in the body long enough that the gap can be twelve weeks.
A few seconds of stinging. Letting it warm to room temperature first makes a noticeable difference.
Tuberculosis and hepatitis before you start, and TB testing often repeated yearly. Beyond that, no routine schedule.
Inject when you remember and count twelve weeks from that day. If you are weeks or months late, call first.
Yes, apart from live ones. The flu shot, COVID vaccines and Shingrix are not live. Have any live ones before starting.
No. It works on a different switch inside the skin cell, the aryl hydrocarbon receptor. That is why there is no time limit and no skin thinning.
Yes — approved for the face and skin folds, one of its main advantages over a steroid.
Most likely folliculitis — small red bumps around hair follicles where you applied it. The most common side effect in the trials, at roughly one in five people, usually mild, and most carried on.
Give it twelve weeks. Some change usually shows by four.
That is a normal way to use it. In the long-term study, many who cleared completely stayed clear for months, then restarted when plaques returned.
Yes, it is also approved for atopic dermatitis, in adults and in children from age two.